Shares in Angle, the Surrey-based technology investment firm, fell today after it reported delays to its IVF product EmbryoSure.The embryo viability product is being developed by Novocellus, which is 82% owned by Angle.The firm had already said the trial of EmbryoSure was delayed, but today added that the timeframe for completing the trials was "at present uncertain". Agnle would meet with Origio, the firm responisble for the trials, at the end of this month to review options for progressing the trials, it said. "We continue to believe that EmbryoSure has the potential to make a major impact in the IVF market and it is important to us that we get the trials completed and the product in the market as quickly as possible," said chief executive Andrew Newland. Angle's share price fell 6% after the announcement.